Paolo Gionchetti
University of Bologna
361 Papers
2.7K Citations
Paolo Gionchetti is an academic researcher from University of Bologna. The author has contributed to research in topics: Ulcerative colitis & Medicine. The author has an hindex of 68, co-authored 324 publications. Previous affiliations of Paolo Gionchetti include University of Zaragoza & University of L'Aquila.
Chat about Author
Papers
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management
Fernando Gomollón,Axel Dignass,Vito Annese,Herbert Tilg,Gert Van Assche,James O. Lindsay,Laurent Peyrin-Biroulet,Garret Cullen,Marco Daperno,Torsten Kucharzik,Florian Rieder,Sven Almer,Alessandro Armuzzi,Marcus Harbord,Jost Langhorst,Miquel Sans,Yehuda Chowers,Gionata Fiorino,Pascal Juillerat,Gerassimos J. Mantzaris,Fernando Rizzello,Stephan R. Vavricka,Paolo Gionchetti +22 more
TL;DR: The methodology of the consensus process, and the classification, diagnosis and medical management of active and quiescent Crohn’s disease of this ECCO Consensus are concerns.
1.8K
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders.
Fernando Magro,Paolo Gionchetti,Rami Eliakim,Sandro Ardizzone,Alessandro Armuzzi,Manuel Barreiro-de Acosta,Johan Burisch,Krisztina Gecse,Ailsa Hart,Pieter Hindryckx,Cord Langner,Jimmy K. Limdi,Gianluca Pellino,Edyta Zagórowicz,Tim Raine,Marcus Harbord,Florian Rieder +16 more
TL;DR: This research presents a meta-analyses of Gastroenterology and Hepatology at the cellular and molecular level, which shows clear trends in the development of immune-oncology-metabolical pathways towards “clinically checkpoints”.
Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial
Paolo Gionchetti,Fernando Rizzello,A. Venturi,Patrizia Brigidi,Diego Matteuzzi,Gabriele Bazzocchi,Gilberto Poggioli,Mario Miglioli,Massimo Campieri +8 more
TL;DR: Oral administration of a probiotic preparation containing 5 x 10 per gram of viable lyophilized bacteria of 4 strains of lactobacilli, 3 strains of bifidobacteria, and 1 strain of Streptococcus salivarius subsp.
1.5K
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial
Paolo Gionchetti,Fernando Rizzello,Ulf Helwig,A. Venturi,Karen M. Lammers,Patrizia Brigidi,Beatrice Vitali,Gilberto Poggioli,Mario Miglioli,Massimo Campieri +9 more
TL;DR: Treatment with VSL#3 is effective in the prevention of the onset of acute pouchitis and improves quality of life of patients with ileal pouch-anal anastomosis.
1.1K
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis
Toshiki Mimura,Fernando Rizzello,Ulf Helwig,Gilberto Poggioli,Stefan Schreiber,Ic Talbot,Rj Nicholls,Paolo Gionchetti,Massimo Campieri,Michael A. Kamm +9 more
TL;DR: The once daily high dose probiotic VSL#3 is effective in maintaining antibiotic introduced remission for at least a year in patients with recurrent or refractory pouchitis, associated with a high level of quality of life.
976